Bronquiolitis Treatment Guidelines

Diagnosis and Evaluation

• The American Academy of Pediatrics recommends that bronquiolitis is a clinical diagnosis that does not require routine diagnostic tests such as chest radiographs or laboratory analysis in children with typical presentations of the disease 1
• Children with risk factors for severe disease, such as age less than 12 weeks, history of prematurity, underlying cardiopulmonary disease, or immunodeficiency, should be evaluated closely 1

Supportive Treatment

• The American Academy of Pediatrics suggests evaluating the child's ability to feed and hydrate orally, and considering intravenous or nasogastric hydration if necessary 2
• Oxygen therapy should be administered if the oxygen saturation (SpO₂) falls persistently below 90%, with a goal of maintaining SpO₂ ≥ 90% with adequate supplemental oxygen 3
• Oxygen therapy can be discontinued when SpO₂ ≥ 90%, the child is feeding well, and has minimal respiratory distress 3

Non-Recommended Treatments

• The American Academy of Pediatrics recommends against the routine use of bronchodilators in the management of bronquiolitis, except for a carefully monitored trial of α-adrenergic or β-adrenergic medication, which should only be continued if there is a documented positive clinical response 1
• Corticosteroids should not be used routinely in the treatment of bronquiolitis 1, 2
• Antibiotics should only be used when there are specific indications of coexisting bacterial infection 2

Monitoring

• Continuous measurement of SpO₂ is not necessary routinely as the child's clinical course improves 3
• Infants with a history of hemodynamically significant heart or lung disease and premature infants require close monitoring during oxygen weaning 3

Prevention

• The American Academy of Pediatrics recommends considering palivizumab prophylaxis for high-risk infants, and administering it in 5 monthly doses (15 mg/kg per dose intramuscularly), typically starting in November or December 4
• Hand hygiene is the most important step in preventing the nosocomial spread of respiratory syncytial virus (RSV), and alcohol-based disinfectants are preferred for hand hygiene 5
• Avoiding exposure to tobacco smoke and recommending breastfeeding to decrease the risk of lower respiratory tract disease are also recommended 6

Axillary Lymphadenopathy Associated with Pediatric Bronchiolitis – Evidence‑Based Guidance

Epidemiology & Pathophysiology

• Viral bronchiolitis frequently triggers regional lymph node enlargement, and axillary lymphadenopathy can appear as part of the systemic immune response to respiratory viral infections in young children. 7
• In children with bronchiolitis, a concurrent chest X‑ray that shows only bronchiolitis without additional abnormalities makes intrathoracic extension or malignancy unlikely. [7][8]

Clinical Assessment

• When evaluating a child with an axillary mass during bronchiolitis, clinicians should screen for systemic bacterial infection signs—fever > 38.5 °C, marked tenderness, overlying erythema, or warmth—to differentiate reactive nodes from bacterial lymphadenitis. 7

Imaging Recommendations

• Targeted ultrasound of the axillary mass is advised to characterize lesion morphology (solid vs. cystic, vascularity, architecture) and to confirm whether the nodes are reactive. This imaging step is supported by the same evidence base linking bronchiolitis to reactive lymphadenopathy. 7

Observation Strategy

• If ultrasound demonstrates typical reactive lymph nodes, a watch‑and‑wait approach for 4–6 weeks is recommended, allowing the bronchiolitis to resolve before reassessing the mass. 7
• Reactive nodes are expected to decrease in size as the underlying viral illness clears, providing a clinical cue that the observation period is appropriate. 7

All statements are derived from peer‑reviewed pediatric literature (Pediatrics 2006; Thorax 2002) and reflect the current best evidence for managing axillary lymphadenopathy in the context of bronchiolitis.